Johnson & Johnson CEO Projects Cancer Cures Within a Decade

At the Wall Street Journal Leadership Institute CEO Summit in London, Johnson & Johnson Chairman and CEO Joaquin Duato announced the company’s aim to “eliminate cancer” within ten years. He cited recent immune-based successes, noting that multiple myeloma patients now have a median survival of about a decade, up from previously “single years.” Duato also highlighted cases where a single treatment produced remission lasting more than five years for patients who had been in hospice.

KTVU Fox 2

The announcement reflects a broader shift toward market-driven biomedical solutions that blend immunotherapy, targeted protein inhibitors, and artificial intelligence (AI). Duato described AI as a “force multiplier” for drug discovery and personalized treatment design. Johnson & Johnson’s recent acquisition of Firefly Bio, a biotech firm that creates molecules to penetrate cancer cells and neutralize proteins linked to complex gene mutations, exemplifies this strategy.

A pharmaceutical giant predicts that a cure for certain types of cancer will become a reality in the next decade

Multiple myeloma now shows a median survival of roughly ten years, up from a few years a decade ago. Select hospice patients have remained in remission for over five years after a single treatment. AI-driven biomarkers are expected to improve early diagnosis and mutation-specific therapy, though exact figures were not disclosed.

A pharmaceutical giant predicts that a cure for certain types of cancer will become a reality in the next decade

If the timeline holds, some cancers could shift from terminal to chronic, manageable conditions, reshaping treatment pathways, insurance models, and survivorship care. Longer life expectancy would intersect with broader longevity technologies, influencing public-health planning and resource allocation.

A pharmaceutical giant predicts that a cure for certain types of cancer will become a reality in the next decade

Duato said Johnson & Johnson is investing in “understanding the biology of cancer growth” and deploying “disruptive technologies” to reverse terminal outcomes, describing the cure goal as realistic while acknowledging that some cancers may become chronic diseases. Dr. Marc Siegel agreed, noting that AI-enabled targeting of mutations and biomarker-based diagnostics will speed both cures and chronic-care strategies. Both executives linked the Firefly Bio acquisition to the ability to address “difficult-to-treat gene mutations.”

A pharmaceutical giant predicts that a cure for certain types of cancer will become a reality in the next decade

• “It is realistic to believe that we will cure certain cancers, and we will turn some others into chronic diseases.” — Joaquin Duato, Chairman & CEO, Johnson & Johnson

A pharmaceutical giant predicts that a cure for certain types of cancer will become a reality in the next decade

• “We have treatments now that utilize your own immune system to attack the cancer ,” — Joaquin Duato, Johnson & Johnson

KTVU Fox 2

• “Advances [will be] based on the use of AI to help guide targeted treatments with expanding knowledge of cancer mutations and how to target them," he predicted, speaking to Fox News Digital.” — Dr. Marc Siegel, Senior Medical Analyst, Fox News

KTVU Fox 2

Johnson & Johnson plans to embed AI platforms in ongoing trials for immunotherapies and Firefly Bio’s targeted agents. Data on multiple myeloma outcomes are slated for release in late 2026, and the firm intends to broaden AI-driven biomarker programs to other solid-tumor indications. Regulators’ review of Firefly Bio’s pipeline will be watched as a gauge of the decade-long cure ambition.

A pharmaceutical giant predicts that a cure for certain types of cancer will become a reality in the next decade